[{"id":"930271d4-4c89-4b12-9340-38647392d747","acronym":"","url":"https://clinicaltrials.gov/study/NCT05732961","created_at":"2023-02-17T15:00:52.691Z","updated_at":"2025-02-25T14:17:40.080Z","phase":"Phase 2","brief_title":"Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms","source_id_and_acronym":"NCT05732961","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" SF3B1","pipe":" | ","alterations":" SF3B1 mutation","tags":["SF3B1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SF3B1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Reblozyl (luspatercept-aamt)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 02/21/2023","start_date":" 02/21/2023","primary_txt":" Primary completion: 06/20/2025","primary_completion_date":" 06/20/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-02-07"},{"id":"99f4875a-0520-4340-a630-53ddf9fb3ea7","acronym":"PRISMM","url":"https://clinicaltrials.gov/study/NCT04447651","created_at":"2021-01-18T21:24:05.813Z","updated_at":"2025-02-25T14:29:23.488Z","phase":"","brief_title":"Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM)","source_id_and_acronym":"NCT04447651 - PRISMM","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" SF3B1 • SRSF2 • U2AF1","pipe":" | ","alterations":" SF3B1 mutation • SRSF2 mutation • U2AF1 mutation","tags":["SF3B1 • SRSF2 • U2AF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SF3B1 mutation • SRSF2 mutation • U2AF1 mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 09/17/2020","start_date":" 09/17/2020","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-08-02"},{"id":"711f8265-575f-4a14-bb60-be585609d334","acronym":"","url":"https://clinicaltrials.gov/study/NCT05024994","created_at":"2021-08-27T12:53:02.872Z","updated_at":"2025-02-25T13:35:55.158Z","phase":"Phase 2","brief_title":"A Study of E7820 in People With Bone Marrow (Myeloid) Cancers","source_id_and_acronym":"NCT05024994","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" FLT3 • IDH1 • SF3B1 • SRSF2 • U2AF1 • ZRSR2","pipe":" | ","alterations":" IDH2 mutation • FLT3 mutation • SF3B1 mutation • SRSF2 mutation • U2AF1 mutation • ZRSR2 mutation","tags":["FLT3 • IDH1 • SF3B1 • SRSF2 • U2AF1 • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • FLT3 mutation • SF3B1 mutation • SRSF2 mutation • U2AF1 mutation • ZRSR2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e E7820"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 08/13/2021","start_date":" 08/13/2021","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-07-03"},{"id":"b4b55ef9-4653-42bf-95e0-84efd373e033","acronym":"","url":"https://clinicaltrials.gov/study/NCT05891249","created_at":"2023-06-06T14:07:08.438Z","updated_at":"2024-07-02T16:34:26.950Z","phase":"Phase 4","brief_title":"A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) \u0026 Beta-thalassemia (β-Thal) in India","source_id_and_acronym":"NCT05891249","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" SF3B1","pipe":" | ","alterations":" SF3B1 mutation","tags":["SF3B1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SF3B1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Reblozyl (luspatercept-aamt)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 06/05/2023","start_date":" 06/05/2023","primary_txt":" Primary completion: 04/13/2026","primary_completion_date":" 04/13/2026","study_txt":" Completion: 04/13/2026","study_completion_date":" 04/13/2026","last_update_posted":"2024-06-12"},{"id":"ec361a88-10be-462e-b8c7-8fa193d6a067","acronym":"","url":"https://clinicaltrials.gov/study/NCT03418038","created_at":"2021-01-18T16:51:47.082Z","updated_at":"2024-07-02T16:35:11.929Z","phase":"Phase 2","brief_title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","source_id_and_acronym":"NCT03418038","lead_sponsor":"Mayo Clinic","biomarkers":" IDH1 • BCL2 • IDH2 • DNMT3A • SF3B1 • TET2 • SRSF2 • U2AF1 • CD4 • ZRSR2","pipe":" | ","alterations":" IDH2 mutation • DNMT3A mutation • TET2 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation","tags":["IDH1 • BCL2 • IDH2 • DNMT3A • SF3B1 • TET2 • SRSF2 • U2AF1 • CD4 • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • DNMT3A mutation • TET2 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • gemcitabine • Rituxan (rituximab) • cytarabine • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • decitabine • dexamethasone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Hemady (dexamethasone tablets) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 03/23/2018","start_date":" 03/23/2018","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-04-02"},{"id":"f6c20e60-2c54-4ca4-a32a-1818b76a2ae4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03770429","created_at":"2021-01-18T18:39:17.898Z","updated_at":"2025-02-25T15:08:09.884Z","phase":"Phase 1","brief_title":"AZD6738 for Patients With Progressive MDS or CMML","source_id_and_acronym":"NCT03770429","lead_sponsor":"Massachusetts General Hospital","biomarkers":" SF3B1 • SRSF2 • U2AF1 • ZRSR2","pipe":" | ","alterations":" SF3B1 mutation","tags":["SF3B1 • SRSF2 • U2AF1 • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SF3B1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ceralasertib (AZD6738)"],"overall_status":"Recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 08/05/2019","start_date":" 08/05/2019","primary_txt":" Primary completion: 05/31/2024","primary_completion_date":" 05/31/2024","study_txt":" Completion: 05/31/2025","study_completion_date":" 05/31/2025","last_update_posted":"2024-03-15"},{"id":"15953f0f-132c-44a4-9f39-8d36bdd31ec9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04278768","created_at":"2021-05-11T14:53:15.390Z","updated_at":"2024-07-02T16:35:15.352Z","phase":"Phase 1/2","brief_title":"Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With AML or MDS","source_id_and_acronym":"NCT04278768","lead_sponsor":"Curis, Inc.","biomarkers":" FLT3 • SF3B1 • U2AF1","pipe":" | ","alterations":" FLT3 mutation • SF3B1 mutation • U2AF1 mutation","tags":["FLT3 • SF3B1 • U2AF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • SF3B1 mutation • U2AF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • emavusertib (CA-4948)"],"overall_status":"Recruiting","enrollment":" Enrollment 366","initiation":"Initiation: 07/06/2020","start_date":" 07/06/2020","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-03-11"},{"id":"1511b518-b2d9-44d0-a52a-ddad9c414044","acronym":"CORONADO CLL","url":"https://clinicaltrials.gov/study/NCT05405309","created_at":"2022-06-06T13:56:17.349Z","updated_at":"2024-07-02T16:35:19.578Z","phase":"Phase 1/2","brief_title":"RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT05405309 - CORONADO CLL","lead_sponsor":"University of Utah","biomarkers":" TP53 • BCL2 • CD20 • SF3B1 • CCND1 • CD5 • POT1 • FCER2","pipe":" | ","alterations":" TP53 mutation • ATM mutation • Chr t(11;14) • SF3B1 mutation","tags":["TP53 • BCL2 • CD20 • SF3B1 • CCND1 • CD5 • POT1 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • ATM mutation • Chr t(11;14) • SF3B1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • camonsertib (RP-3500)"],"overall_status":"Recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 09/23/2022","start_date":" 09/23/2022","primary_txt":" Primary completion: 08/15/2025","primary_completion_date":" 08/15/2025","study_txt":" Completion: 08/15/2027","study_completion_date":" 08/15/2027","last_update_posted":"2024-02-13"},{"id":"b5a9bf94-a0bf-4a0f-b85d-89df1fb88d99","acronym":"","url":"https://clinicaltrials.gov/study/NCT03204188","created_at":"2021-01-18T15:48:00.906Z","updated_at":"2024-07-02T16:35:27.918Z","phase":"Phase 2","brief_title":"Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","source_id_and_acronym":"NCT03204188","lead_sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","biomarkers":" TP53 • SF3B1","pipe":" | ","alterations":" TP53 mutation • NOTCH1 mutation • SF3B1 mutation","tags":["TP53 • SF3B1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • NOTCH1 mutation • SF3B1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Imbruvica (ibrutinib) • fludarabine IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 09/22/2017","start_date":" 09/22/2017","primary_txt":" Primary completion: 07/18/2022","primary_completion_date":" 07/18/2022","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-11-28"},{"id":"eecc0761-d3fa-49cf-82cd-389c0096a5df","acronym":"LUSPLUS","url":"https://clinicaltrials.gov/study/NCT05181592","created_at":"2022-01-06T22:53:42.390Z","updated_at":"2025-02-25T14:16:35.136Z","phase":"Phase 3","brief_title":"Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome.","source_id_and_acronym":"NCT05181592 - LUSPLUS","lead_sponsor":"GWT-TUD GmbH","biomarkers":" SF3B1","pipe":" | ","alterations":" SF3B1 mutation • Chr del(5q)","tags":["SF3B1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SF3B1 mutation • Chr del(5q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Reblozyl (luspatercept-aamt)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 10/27/2021","start_date":" 10/27/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2023-10-12"},{"id":"0498e653-58b8-4f7a-ba46-3446c5b95b95","acronym":"","url":"https://clinicaltrials.gov/study/NCT05983237","created_at":"2023-08-09T14:09:26.536Z","updated_at":"2024-07-02T16:35:40.277Z","phase":"Phase 1/2","brief_title":"Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma","source_id_and_acronym":"NCT05983237","lead_sponsor":"Jun Guo","biomarkers":" SF3B1","pipe":" | ","alterations":" SF3B1 mutation","tags":["SF3B1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SF3B1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • AiRuiKa (camrelizumab) • AiRuiYi (fluzoparib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 08/31/2023","start_date":" 08/31/2023","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-08-11"},{"id":"5a55c8ba-84c1-4c67-a725-dab20754576f","acronym":"FISiM-Luspa","url":"https://clinicaltrials.gov/study/NCT05520749","created_at":"2022-08-30T20:55:51.039Z","updated_at":"2024-07-02T16:35:55.523Z","phase":"","brief_title":"Efficacy and Safety of Luspatercept: A Study by Fondazione Italiana Sindromi Mielodisplastiche","source_id_and_acronym":"NCT05520749 - FISiM-Luspa","lead_sponsor":"Fondazione Italiana Sindromi Mielodisplastiche-ETS","biomarkers":" SF3B1","pipe":" | ","alterations":" SF3B1 mutation","tags":["SF3B1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SF3B1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Reblozyl (luspatercept-aamt)"],"overall_status":"Completed","enrollment":" Enrollment 215","initiation":"Initiation: 01/01/2022","start_date":" 01/01/2022","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 01/31/2023","study_completion_date":" 01/31/2023","last_update_posted":"2023-02-15"},{"id":"de27d4a7-da28-4adb-9c83-edc82f6ec299","acronym":"MEDALIST","url":"https://clinicaltrials.gov/study/NCT02631070","created_at":"2021-01-18T12:47:39.328Z","updated_at":"2025-02-25T16:15:32.760Z","phase":"Phase 3","brief_title":"A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes","source_id_and_acronym":"NCT02631070 - MEDALIST","lead_sponsor":"Celgene","biomarkers":" SF3B1","pipe":" | ","alterations":" SF3B1 mutation","tags":["SF3B1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SF3B1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Reblozyl (luspatercept-aamt)"],"overall_status":"Completed","enrollment":" Enrollment 229","initiation":"Initiation: 02/09/2016","start_date":" 02/09/2016","primary_txt":" Primary completion: 06/18/2019","primary_completion_date":" 06/18/2019","study_txt":" Completion: 11/26/2020","study_completion_date":" 11/26/2020","last_update_posted":"2021-12-17"}]